Leukemia Clinical Trials in Leuven
17 recruitingLeuven, Belgium
Showing 1–17 of 17 trials
Recruiting
Phase 3
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Leukemia, Myeloid, Acute
Janssen Research & Development, LLC600 enrolled238 locationsNCT06852222
Recruiting
Phase 3
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines630 enrolled155 locationsNCT06943872
Recruiting
Phase 3
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
Acute Myeloid Leukemia
University of Ulm650 enrolled91 locationsNCT04628026
Recruiting
Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC700 enrolled174 locationsNCT01804686
Recruiting
Phase 3
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaLeukemia, B-cell+1 more
Loxo Oncology, Inc.662 enrolled144 locationsNCT05254743
Recruiting
Phase 2
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Loxo Oncology, Inc.249 enrolled133 locationsNCT06588478
Recruiting
Phase 3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Leukemia
Daiichi Sankyo700 enrolled292 locationsNCT06578247
Recruiting
Phase 1
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
Chronic Myeloid LeukemiaCMLChronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Enliven Therapeutics200 enrolled46 locationsNCT05304377
Recruiting
Phase 3
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Acute Lymphoblastic LeukemiaMixed Phenotype Acute Leukemia
Princess Maxima Center for Pediatric Oncology160 enrolled112 locationsNCT05327894
Recruiting
European Myeloma Network (EMN) Sample Project
Multiple MyelomaSmoldering Multiple MyelomaPlasma Cell Leukemia+2 more
European Myeloma Network B.V.6,000 enrolled41 locationsNCT06237803
Recruiting
Not Applicable
PTX3-targeted Antifungal Prophylaxis
Acute Myeloid LeukemiaGenetic PredispositionCandidiasis+2 more
Bochud Pierre-Yves410 enrolled9 locationsNCT03828773
Recruiting
Phase 3
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Leukemia, Acute Lymphoblastic
Mats Heyman6,430 enrolled130 locationsNCT04307576
Recruiting
Phase 3
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Acute Myeloid Leukemia
Stichting Hemato-Oncologie voor Volwassenen Nederland227 enrolled119 locationsNCT07075016
Recruiting
Phase 1Phase 2
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, Acute
Sumitomo Pharma America, Inc.362 enrolled92 locationsNCT04988555
Recruiting
Phase 3
Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML
Acute Myeloid Leukemia (AML) in RemissionStem Cell Transplantation
Vastra Gotaland Region170 enrolled17 locationsNCT05477589
Recruiting
Phase 2
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
Hodgkin LymphomaNon-Hodgkin LymphomaMultiple Myeloma+7 more
University of Liege114 enrolled10 locationsNCT03852407
Recruiting
Phase 1
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Celyad Oncology SA27 enrolled5 locationsNCT04167696